The field keeps treating psychedelic clinical validation as a future-tense problem. After Definium Therapeutics’ DT120 cleared Phase 3 in both major depressive disorder and generalized anxiety disorder, it isn’t anymore. Two pivotal wins, two indications, one LSD formulation. The question that mattered two years ago, whether this class of compounds could survive randomized controlled scrutiny, has been answered. The question that matters now is harder: which patients, which sessions, and what happens when the protocol meets the clinic.

I ask that from a specific vantage point. Having treated more than 30,000 patients with guided ketamine therapy through Mindbloom, I’ve watched a rapid-acting mechanism move from “promising signal” to standard-of-care infrastructure, with all the friction that journey creates. Definium is now at the same threshold ketamine crossed a decade ago, except the session economics, the integration requirements, and the regulatory novelty are all simultaneously larger.

What Two Phase 3 Wins Actually Prove

The DT120 program, formerly developed under the MindMed name as MM120, built on a Phase 2 signal robust enough to earn FDA Breakthrough Therapy Designation for GAD in March 2024. The Voyage trial confirmed what that designation anticipated: a single-dose formulation producing statistically significant, clinically meaningful anxiety reduction. The Emerge study had already done the same for depression using the Montgomery-Ã…sberg Depression Rating Scale at Week 6. Two independent Phase 3 programs, two primary endpoints cleared. That is not noise.

What makes this mechanistically interesting alongside ketamine is the convergence on rapid-acting antidepressant and anxiolytic effects through completely different receptor profiles. Ketamine works primarily through NMDA antagonism, producing dissociation and antidepressant effects within hours. DT120 works through serotonergic agonism, particularly at 5-HT2A receptors, producing a qualitatively different altered state over a longer session window. Both produce durable effects from a single acute intervention. That shared outcome through divergent mechanisms suggests something important about the neurobiology of treatment-resistant mood and anxiety states: plasticity, not just receptor occupancy, may be the therapeutic substrate. Compass Pathways’ COMP360 clearing its second Phase 3 in treatment-resistant depression adds psilocybin to that convergence, making it harder to dismiss the class effect as compound-specific luck.

In my practice, the patients who respond most durably to ketamine are not always the ones with the highest baseline severity scores. They are often patients who can tolerate ambiguity during the dissociative state, who have sufficient psychological scaffolding to metabolize an acute neurobiological shift into a new behavioral baseline. A Phase 2 biomarker study in psilocybin-assisted therapy for GAD found that only 44% of participants responded and 27% achieved remission, and identified a four-gene expression panel predicting who those responders would be. If something comparable exists for LSD-based therapy, the Voyage and Emerge datasets are large enough to find it. Nobody should file an NDA without running that analysis.

The Protocol Assumptions That Won’t Survive the Clinic

Here is the design implication the field is not discussing loudly enough. LSD session protocols in research settings run eight to twelve hours of supervised contact per treatment day, a structural requirement no current reimbursement framework is built to absorb. Ketamine, even in its IV form, runs two to four hours per infusion. Esketamine in the REMS program requires two hours of post-dose monitoring. The FDA’s esketamine approval pathway created a supervised administration model that took years to operationalize at scale, and that was for a shorter session with a well-characterized safety profile. LSD’s session length is not a minor logistical footnote. It is the central implementation challenge, and trial protocols have so far treated it as someone else’s problem to solve at the commercialization stage.

There is also a population-level enrollment problem accumulating quietly. In my bilingual clinical work across 36 states, GAD in Spanish-speaking patients presents with high somatic burden, significant stigma around altered-state therapies, and near-zero representation in psychedelic trial cohorts. The patients carrying the greatest unmet burden in anxiety disorders are the least likely to have been in the Voyage trial. If the approved label eventually reflects a sample that skewed toward English-fluent, high-health-literacy participants with no comorbid SUD, the generalizability gap will be real and the field will spend years catching up to it.

I’m watching for Definium’s NDA submission timeline and any signal from FDA on how they intend to handle the session-supervision REMS question for a full-agonist psychedelic. That regulatory conversation will set the structural template for the entire class, and it is going to be more consequential than any single efficacy readout.

References

  1. FierceBiotech — “Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety”
  2. Pharmaphorum — “Definium chalks new phase 3 win with LSD-based therapy” (Voyage GAD trial)
  3. HMP Global Learning Network — “Single-Dose LSD Formulation Hits Primary Endpoint in Phase 3 MDD Trial” (Emerge study)
  4. Phillips Lytle — FDA Breakthrough Therapy Designation for MM120/DT120 in GAD (March 2024)
  5. Compass Pathways — “Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression”
  6. Pharmacy Times — “Esketamine Receives FDA Approval for Adults with Treatment-Resistant Depression”
  7. International Journal of Neuropsychopharmacology — Biomarker study: 44% response rate in psilocybin-assisted therapy for GAD, four-gene predictive panel
+ posts

Dr. Leonardo Vando, MD is Principal Investigator of Psychiatry at Vando Medical Services.